← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Neuronascent, Inc.
Clarksville, MD
$7,321,514
Total funding
2
Grants
Funding over time
peak $2.4M · FY2018–24$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,321,514 · 2
By mechanism
U01$4,543,556 · 1
R01$2,777,958 · 1
Investigators at Neuronascent, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial$2,100,000
U01 · FY2023 · AG
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial$2,093,556
U01 · FY2024 · AG
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$1,575,691
R01 · FY2018 · AG
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$692,120
R01 · FY2019 · AG
Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial$350,000
U01 · FY2024 · AG
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$263,516
R01 · FY2019 · AG
Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD$246,631
R01 · FY2021 · AG